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Available online 25 March 2009Background: MRS studies of acutely depressed patients reveal decreased levels of total
glutamate and glutamine (Glx) in frontal cortex which may reﬂect abnormalities of glutamate–
glutamine cycling through astrocytes. Frontal Glx levels appear to be normalised after recovery
from depression, but it is not known if this composite measure masks ongoing differences in
glutamate or glutamine alone.
Methods: Medication-free, fully recovered patients with a history of DSM-IV recurrent major
depressive disorder (n=14) and healthy controls (n=16) were scanned at 3T. Short echo time
PRESS and PRESS-J spectra were acquired from a 12 cm3 voxel of frontal cortex incorporating
the anterior cingulate.
Results: Levels of Glx and of glutamate alone did not differ between groups. However, myo-
inositol concentrations were signiﬁcantly higher in those with a history of depression than in
controls.
Limitations: Abnormal MRSmeasureswere not demonstrated during episodes of depression for
these participants, so any evidence of changes with recovery is indirect.
Conclusions: The normal glutamatergic measures combined with elevated levels of the
astrocytic marker, myo-inositol, suggest that recovery from depression may be associated with
changes in glial function in frontal cortex.
© 2009 Elsevier B.V. Open access under CC BY license.Keywords:
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Frontal cortex1. Introduction
There is a growing interest in the role of brain glutamate
mechanisms in depression (Sanacora et al., 2008), heightened
by the observation that drugs altering glutamate activity such
as the NMDA receptor antagonist, ketamine, and the
glutamate release inhibitor, riluzole, may have beneﬁcial
effects in patients with treatment resistant depression
(Sanacora et al., 2004; Zarate et al., 2006).
Measuring glutamate activity in the brain in humans pres-
ents challenges but theuse ofmagnetic resonance spectroscopy
(MRS) provides a useful approach. Several studies have applied
protonMRS to study glutamate levels in depression and overallPsychiatry, Warneford
865 226466; fax: +44
.J. Taylor).
Y license.the evidence suggests that acutely depressed patients have
decreased levels of Glx (a composite measure of glutamate and
glutamine) in anterior brain regions (Auer et al., 2000; Hasler
et al., 2007; Yildiz-Yesiloglu and Ankerst, 2006). Interestingly a
largeMRS studyof occipital cortex reportedanoppositeﬁnding,
namely that acutely depressed patients had increased gluta-
mate levels (Sanacora et al., 2004), suggesting potential
regional brain differences in Glx regulation in depression.
In contrast, there have been few studies of Glx levels in
recovereddepressedpatients but such information is important
in determining the pathophysiological role of glutamate in
vulnerability to depression. Our group found increased levels of
Glx in occipital cortex in recovered unmedicated depressed
patients (Bhagwagar et al., 2007), consistentwith the increased
concentrations of glutamate reported in this brain region in
acute depression. However, when we examined Glx levels in a
subset of these participants in anterior cingulate cortex we
found no difference betweenpatients and controls (Bhagwagar
Table 1
Group characteristics.
Recovered depression
(n=14)
Controls
(n=16)
Age (mean and range) 32.6 (18–57) 31.8 (19–63)
Gender 4M, 10F 5M, 11F
Smoking history 5 smokers 3 smokers
Beck Depression Inventory 2.7 (3.1) 1.4 (1.5)
Hamilton Depression Rating Scale 0.3 (0.5) 0.1 (0.5)
Spielberger Trait Anxiety 36.2 (9.7) 30.1 (5.3) ⁎
Spielberger State Anxiety 31.5 (8.7) 30.9 (6.2)
Age of onset 22 (10.8)
Number of episodes 2.6 (1.2)
Lifetime melancholic depression 3
Lifetime history of suicide attempts 6
Months since last antidepressant
treatment (mean and range)
38 (8–84)
Glx/creatine 1.61 (0.15) 1.69 (0.21)
Myo-inositol/creatine 0.86 (0.07) 0.78 (0.09) ⁎
N-acetylaspartate/creatine 1.08 (0.09) 1.11 (0.15)
Choline/creatine 0.31 (0.04) 0.29 (0.02)
Glutamate/creatine 1.58 (0.23) 1.66 (0.16)
Mean values with standard deviation unless otherwise stated.
⁎ pb0.05 t-test.
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lation in patients with mood disorder. Hasler et al. (2005) also
found normal Glx levels in anterior cingulate cortex in re-
covered depressed participants. The aim of the present study
was to examine Glx levels in anterior cingulate cortex in a
further group of recovered depressed patients. In addition,
because levels of glutamate and glutamine can vary indepen-
dently of each other we used a further MRS technique, PRESS-J,
which permits measurement of glutamate without glutamine
at moderate ﬁeld strengths (Hurd et al., 2004).
2. Materials and methods
2.1. Participants
Medication-free, fully recovered patients with a history of
recurrentmajordepressivedisorder, diagnosedby theStructured
Clinical Interview for DSM-IV (n=14; 4M, 10F) and healthy
controls (n=16; 5M,11F) were recruited. All were euthymic for
at least three months, and had received no psychotropic
medication within three months (mean=38 months; range
8–84 months); three patients were drug naïve. Nine patients
had a family history of mood disorder. Three of the recovered
depressed patients had co-morbid illnesses; one had social
phobia, and two subjects had a history of alcoholmisuse but not
dependence. On the day of scanning, mental state ratings were
performed with the Hamilton Depression Rating Scale, Beck
Depression Inventory, and Spielberger State and Trait Anxiety
scales. All participants gave written informed consent to the
study, which was approved by the Oxfordshire Research Ethics
Committee, UK.
2.2. MRS methodology
Scanningwas performed on a 3T Varian INOVA systemwith
a head optimised gradient coil (Tesla Engineering, Storrington,
UK) and a head-only transmit/receive quadrature birdcage RF
coil. Datawere acquired from a 30×20×20mmvoxel placed in
medial prefrontal and anterior cingulate cortex anterior to the
genu of the corpus callosum. The voxel was positioned
manually by reference to an axial T1-weighted gradient-echo
imagewith the base of the voxel on a plane running through the
genu and splenium of the corpus callosum.
PRESS data with water suppression (TE 26 ms, TR 3 s, 64
averages), and without (TE 26 ms, TR 3 s) were acquired.
PRESS-J data (Hurd et al., 2004) with and without water
suppression were similarly acquired with TE arrayed from
35ms to 185ms in 10ms increments (water-suppressed data,
total acquisitions=128; non-water suppressed data, total
acquisitions=16; TR=3 s). T1-weighted structural images of
whole brain were acquired with 2 mm3 voxel resolution.
PRESS data were analysed with LCModel software (Pro-
vencher, 1993), using the non-water suppressed data for eddy
current correction, calculating metabolite concentrations rela-
tive to creatine in conventional fashion using metabolite basis
spectra (alanine, aspartate, creatine, GABA, glucose, glutamine,
glutamate, glycerophosphocholine, phosphocholine, lactate,
myo-inositol, N-acetylaspartate, N-acetylaspartylglutamate,
scyllo-inositol, taurine) and simulated lipid andmacromolecule
components. PRESS-J spectrawere zero-order phased, apodised
with a 5 Hz Gaussian ﬁlter, and summed (Hurd et al., 2004)before analysis. Glutamate levels relative to creatine were
measured using AMARES (Advanced method for accurate,
robust and efﬁcient spectral ﬁtting) (Vanhamme et al., 1997)
since metabolite basis spectra were not available for PRESS-J
acquisitions, and the spectral simpliﬁcation and ﬂat baselines
obtained with this technique in vivo make direct single peak
ﬁtting reliable (Hurd et al., 2004). Concentrations in proton
MRS studies are conventionally expressed relative to creatine
whichacts as an internal reference standard in the voxel (see for
example, Sanacora et al., 2004; Hasler et al., 2005); levels
relative to tissue water were also calculated but not included
here for reasons of space.
FSL FAST (Zhang et al., 2001) was employed to segment
the structural brain images into grey matter, white matter,
and CSF, to allow estimation of voxel composition.
2.3. Statistical analysis
Statistical analyses were performed in SPSS version 15. To
guard against type I error, the available MRS measures (Glx,
glutamate, myo-inositol, choline, and N-acetylaspartate)
were initially compared between groups by multivariate
analysis using Wilks' lambda. Two-tailed univariate analysis
for each measure independently was then performed to
identify the basis of any overall group effect. The sensitivity of
effects to the inclusion or exclusion of covariates (age and
voxel composition) was tested. Group demographics and
clinical characteristics were compared by t-test. Power
calculations indicated that a sample size of 30 would have
80% power to detect a 10% difference in Glx/Cr between
groups at 0.05 signiﬁcance level. This is the size of difference
typically seen in studies of depressed patients (Auer et al.,
2000; Hasler et al., 2007; Yildiz-Yesiloglu and Ankerst, 2006).
3. Results
Participants with previous episodes ofmajor depression did
not differ signiﬁcantly from controls in age, or on ratings of
current symptoms of depressionor anxiety (Table 1). Therewas
Fig. 1. Individual estimates (points) and group means (bars) for levels of glutamate and glutamine (Glx), glutamate, and myo-inositol in healthy controls (n=16)
and medication-free patients recovered from depression (n=14). Levels expressed relative to creatine. (⁎, F(1,28)=7.49, pb0.02).
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depressive illness (36.2±2.6 vs 30.1±1.3, p=0.04).
The voxels measured contained predominantly grey matter
(69%). Multivariate analysis of MRS results revealed a sig-
niﬁcant difference between the groups (Wilks' lambda=0.624,
F(5,24)=2.894, p=0.035). However this difference was not
explained by glutamatergic abnormalities, since levels of Glx
and glutamate did not differ between groups (pN0.2 in both
cases; Fig. 1, Table 1). Interestingly, myo-inositol levels were
signiﬁcantly elevated in those with a history of major depres-
sive disorder (F(1,28)=7.49, pb0.02; Fig.1, Table 1). The eleva-
tion of myo-inositol was robust to inclusion of age and voxel
composition as covariates (F(1,24)=7.611, pb0.02). The groups
did not differ on other MRS measures (NAA, choline, creatine),
nor in voxel composition (pN0.1 in each case, Table 1). All
ﬁndings were robust to the inclusion of voxel grey and white
matter composition as covariates.
4. Discussion
Our ﬁndings suggest that both Glx (glutamate and gluta-
mine) and glutamate alone as measured by proton MRS at 3Tare normal in the anterior cingulate cortex of recovered
depressed patients withdrawn from medication. Therefore,
based on the results of studies in acutely depressed patients,we
conclude that the low Glx concentration in anterior brain
regions detected by MRS is likely to be a state marker of acute
depression. This contrasts with ﬁndings in occipital cortex,
where levels are apparently elevated in both acutely ill and
recovereddepressedpatients (Bhagwagaret al., 2007; Sanacora
et al., 2004).
In some contexts, Glx estimates include a small compo-
nent (b10%) attributable to GABA (Sanacora et al., 2008).
Reports conﬂict as to whether reduced levels of GABA are
found in the anterior cortex of recovered depressed patients
(Bhagwagar et al., 2008; Hasler et al., 2005). In the absence of
speciﬁc GABA measurements, the data reported here cannot
clarify this point since, at most, the reduction in GABA would
be reﬂected by a 1% difference in Glx levels which is beyond
the statistical power of this study.
The conclusion that glutamatergic abnormalities in anterior
brain regions are markers of the acute depressive state should
be treated as tentative until further studies can be performed.
For example, the current group of recovered depressed patients
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anterior cingulate cortex when acutely depressed. In particular
our data cannot exclude the possibility that persistent gluta-
matergic abnormalities exist in a subgroup of patients. These
questions could be clariﬁed by a larger longitudinal study of
these measures in depressed patients at different phases of
their illness.
MRSmetabolite concentrations in this studywere expressed
relative to creatine, which is conventional when proton MRS is
used. However, this is unlikely to have affected the study
conclusions since analyses referencing to tissuewater found the
same pattern of ﬁndings (data not shown). It is quite possible
that more subtle abnormalities in glutamate mechanisms, for
example in glutamate receptor populations could be present
in recovered depressed patients but not detectable by MRS
(Sanacora et al., 2008). Why recovered depressed patients
should apparently have persistent increases in Glx in occipital
cortex (Bhagwagar et al., 2007) is not clear at present.
Our ﬁnding of elevated levels of myo-inositol in the
recovered depressed patients was unexpected. In previous
studies of anterior cingulate cortex in acute depression, one
studywithparticipants of a similar age range to those described
here (Coupland et al., 2005) found decreased myo-inositol,
whereas two studies in older populations found no signiﬁcant
difference (Auer et al., 2000; Kumar et al., 2002). Similarly, in
studies using voxels placed predominantly in frontal white
matter, thosewith similar age ranges to the current study found
lower levels of myo-inositol in acute depression (Frey et al.,
1998; Gruber et al., 2003), whereas levels were elevated in a
more elderly sample (Kumar et al., 2002). The reason for this
apparent effect of age on myo-inositol levels in depression in
not known, although it has been hypothesised that it may
reﬂect increased probability of reactive gliosis in more elderly
populations (Coupland et al., 2005).
Inositol and related compounds have an important role as
intracellular second messengers; however the MRS-visible
signal in brain appears predominantly to reﬂect myo-inositol
actively accumulatedwithin astrocytes where it is employed as
an osmolyte (Brand et al., 1993). Thus elevated myo-inositol, as
well as normalised glutamate and glutamine, after recovery
fromdepressionmay reﬂect changes in glial function. Glia plays
a key role in the regulation of glutamate neurotransmission
though the process of glutamate–glutamine cycling (Sanacora
et al., 2008), making it possible that changes in this process
during recovery from depression might account for both
normalisation of Glx levels and increases in myo-inositol. This
hypothesis could be tested by using carbon-13 MRS which
permits the measurement not only of overall glutamate levels,
but also rates of glutamate–glutamine cycling through glia
(Shen et al., 1999).
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